Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study
source: The Pediatric Infectious Disease Journal
year: 2017
authors: Sirima SB, Tiono A, Gansané Z, Siribié M, Zongo A, Ouédraogo A, François N, Strezova A, Dobbelaere K, Borys D.
summary/abstract:BACKGROUND:
Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were evaluated in children with sickle cell disease (SCD), who are at increased risk for infections.
METHODS:
In this phase III, open-label, single-center, controlled study in Burkina Faso (NCT01175083), children with SCD (S) or without SCD (NS) were assigned to 6 groups (N = 300): children 8-11 weeks of age ( RESULTS:
One month postprimary vaccination, for each vaccine serotype ≥98% of infants in the CONCLUSIONS:
PHiD-CV was immunogenic with an acceptable safety profile in children with and without SCD starting vaccination at 8 weeks to 23 months of age.
DOI: 10.1097/INF.0000000000001518
read more full text
Related Content
-
Treatment options for sickle cell disease – chronic blood transfusionsBlood transfusions are scheduled and giv...
-
Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemiaSilent cerebral infarction (SCI) is the ...
-
The Family Perspectivehttp://www.sicklecelltransplantconsortiu...
-
Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic PartnershipSickle Cell Disease Association of Ameri...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution net...Emmaus Life Sciences, Inc. announces...
-
Review Board Finds Global Blood’s Sickle Cell Disease Therapy Voxelotor Is SafeAn independent review board has found Gl...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.